Summary
In this multi-institutional phase II study, VM-26 or Teniposide was administered to forty-two patients with advanced colorectal cancer. Patients were initially treated at 60 mg/M2 daily for 5 days with dose adjustments depending on toxicity. One complete response and one partial response were observed lasting six and four months respectively. Leukopenia was severe in 40% of patients. No drug related deaths were seen. In this Southwest Oncology Group (SWOG) study, VM-26 appeared to have minimal benefit in advanced colorectal cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wampler GL, Schultz JJ, Mueller JM, Speckhart J, Taub RN: Pilot Study of 5-Fluorouracil + Teniposide in Treatment of Advanced Colorectal Carcinoma. (Abstr) Proc Amer Soc Clin Oncol 22:452, 1981
Woods RL, Fox RM, Tattersall MHN: Treatment of Small Cell Carcinoma with VM-26. Cancer Treat Rep 63:2011–2013, 1979
Oishi N, Berenberg J, Blumenstein BA, Johnson K, Rivkin SE, Bukowski RM, O'Bryan RM, Stephens RL, Quagliana J, Saiers JH, Crawford ED: Teniposide in Metastatic Renal and Bladder Cancer: A Southwest Oncology Group Study. Cancer Treat Rep 71(12):1307–1308, 1987
Locker GY, Lanzotti V, Khandekar JD: Phase II Trial of Teniposide in Previously Treated and Untreated Patients with Advanced Colorectal Carcinoma: An Illinois Cancer Council Trial. Cancer Treat Rep 70(2):307–308, 1986
Locker GY, Lanzotti V, Khandekar J, Sweet D, Shaw J, Krauss S, Chernicoff D, Bitran J, Stiff P, Miller S, Johnson C: VM-26 in Advanced Adenocarcinoma of the Colon and Rectum: An Illinois Cancer Council Phase II Study. (Abstr) Proc Amer Soc Clin Oncol 3:134, 1984
O'Dwyer PJ, Alonso MT, Leyland-Jones B, Marsoni S: Teniposide: A Review of 12 Years of Experience. Cancer Treat Rep 68:1455–1464, 1984
Dombernowsky P, Nissen NI, Larsen V: Clinical Investigation of a New Podophyllum Derivative, Epipodophyllotoxin, 4′ -Demethyl-9-(4,6-O-2-thenylidene-β-D-glucopyranoside) (NSC-122819), in Patients with Malignant Lymphomas and Solid Tumors. Cancer Chemother Rep 56:71–82, 1972
Spremulli E, Schulz JJ, Speckhart VJ, Wampler GL: Phase II Study of VM-26 in Adult Malignancies. Cancer Treat Rep 64:147–149, 1980
Author information
Authors and Affiliations
Additional information
Address for offprints: Southwest Oncology Group (SWOG 8426), Operations Office, 5430 Fredericksburg Road, Suite #618, San Antonio, TX 78229, USA
Rights and permissions
About this article
Cite this article
Oishi, N., Fleming, T.R., Laufman, L. et al. VM-26 in colorectal carcinoma: A Southwest Oncology Group study. Invest New Drugs 8, 93–95 (1990). https://doi.org/10.1007/BF00216931
Issue Date:
DOI: https://doi.org/10.1007/BF00216931